ClinicalTrials.gg

Program

ficerafusp alfa

Also written as “Ficerafusp alfa” and “BCA101”.

Its studies are mostly in Squamous Cell Carcinoma of Head and Neck, led by Bicara Therapeutics.

Furthest: phase 3, since Jan 10, 20253 company-led studies, 3 open or runningNext primary completion: Oct 31, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bicara Therapeutics33 open or runningphase 3since Jan 10, 2025Jun 10, 2020Oct 31, 2027phase 1 · NCT04429542

Also a collaborator on its studies: Merck.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 10, 2020First study: phase 1 study in Squamous Cell Carcinoma of Head and NeckFirst studyNCT04429542 · 473 planned · United States, Australia, Canada
  2. Jan 10, 2025Phase 3 study in Squamous Cell Carcinoma of Head and NeckNCT06788990 · 650 planned · United States, Argentina, Australia and more
  3. Aug 18, 2026Phase 2 study in Squamous Cell Carcinoma of Head and NeckNCT07807163 · 160 planned · United States

Ahead

  1. Oct 31, 2027Primary completion: phase 1 study in Squamous Cell Carcinoma of Head and NeckNCT04429542
  2. Mar 2028Primary completion: phase 2 study in Squamous Cell Carcinoma of Head and NeckNCT07807163
  3. Apr 2028Primary completion: phase 3 study in Squamous Cell Carcinoma of Head and NeckNCT06788990

TargetBeta

EGFR →TGFB1 →read by rule
“A bifunctional monoclonal antibody targeting both the receptor tyrosine kinase epidermal growth factor receptor (EGFR) and the pro-inflammatory cytokine human transforming growth factor beta (TGF-beta; TGFb), ”NCIt, by rule

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07807163Squamous Cell Carcinoma of Head and Neck · United States2RecruitingMar 2028160
NCT06788990Squamous Cell Carcinoma of Head and Neck · United States, Argentina, Australia and more3RecruitingApr 2028650
NCT04429542Squamous Cell Carcinoma of Head and Neck · United States, Australia, Canada1RecruitingOct 31, 2027473

How it is read

Names in the registry

  • “Ficerafusp alfa”, 2 entries
  • “BCA101”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.